Question explored with the scientific record
How safe is rituxamab
Rituximab is a potent immune-system weapon with serious and well-documented risks. The burden of proof for its use is high, and the evidence shows it regularly causes infections, neutropenia, and other harms that require close monitoring.
The bulk of the evidence on rituximab’s safety comes from studies in cancer and autoimmune disease, almost always in patients already on other strong drugs. A large meta-analysis of lymphoma trials found that adding rituximab to chemotherapy raised the odds of grade 3-4 fever (OR 4.18) and leukocytopenia (OR 1.32) compared to chemo alone [11]. Another study of rituximab in autoimmune diseases found a one-year rate of late-onset neutropenia of 6.6%, meaning more than 6 in 100 patients developed a dangerously low white blood cell count [6]. This risk rose over time, reaching 13.5% at five years [6]. The neutropenia is real and can appear weeks after the infusion [7, 12].
Infusion reactions are common. Across multiple sclerosis studies, about 40-70% of patients had some reaction during the first infusion, though most were mild to moderate [1, 5]. In a study of rituximab for a rare Castleman disease, 70% of patients had an infusion reaction [3]. A 2020 systematic review of the related drug ocrelizumab (same mechanism) in multiple sclerosis estimated that about 26% of patients had infusion reactions, and about 39% experienced an infection [4].
The infection risk is significant. The same review found that across over 3,000 patients, about 39% had some infection [4]. A major concern is reactivation of hepatitis B virus in people who have had a past, resolved infection. A meta-analysis of lymphoma patients found a pooled reactivation rate of 6.3% in people who had previously cleared the virus, with some studies reporting rates as high as 24-29% [10]. This can cause severe liver injury and death [8]. Screening for hepatitis B before starting rituximab is essential, but a real-world study found this was not done in over 47% of cases [9].
| Known Risk | Rate or Finding | Population Studied |
|---|---|---|
| Late-onset neutropenia | 6.6% at 1 year, 13.5% at 5 years [6] | Autoimmune disease |
| Infection (any) | Up to 39% [4] | Multiple sclerosis (ocrelizumab) |
| HBV reactivation (resolved infection) | ~6.3% pooled, up to 29% [10] | Lymphoma |
| Infusion reaction | 41-70% of patients [1, 3] | MS and rare diseases |
Many of these studies were funded by the drug manufacturers. The landmark lymphoma trial that established rituximab’s benefit was funded by Hoffmann-La Roche [2]. The systematic safety review of ocrelizumab (an almost identical drug) noted sponsor involvement [4]. This does not mean the data is wrong, but in a system where the maker pays for the research on its own product, the chance that harms are minimized or unreported is higher than zero.
Separating proven from asserted: it is proven that rituximab causes neutropenia, infusion reactions, and increases risk of infection and hepatitis reactivation. What is not proven is the net benefit for every person with every condition at every dose. The evidence for benefit is strongest in specific cancers like diffuse large B-cell lymphoma and follicular lymphoma [11]. For off-label uses like multiple sclerosis, the evidence is less rigorous [1]. For the healthy person asking "how safe is this?", rituximab is not a vaccine given to prevent a future risk; it is a therapy for active disease. Its safety profile is that of a serious immunosuppressive drug, and the decision to use it requires weighing the real harms above against the specific severity of the disease being treated.
My call: rituximab carries well-documented, serious risks including high rates of infection and a significant chance of late-onset neutropenia. The evidence base is heavily funded by its manufacturers, and the long-term safety data in non-cancer populations is thinner than it should be. Use only for clear, severe disease where the benefit clearly outweighs these known harms. Confidence: moderate.
Sources used 12
-
Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland
A Finnish single-center retrospective study evaluating off-label rituximab use in multiple sclerosis shows reduced relapses and gadolinium-enhancing MRI lesions in relapsing-remitting and secondary progressive MS, with generally good tolerability but notable neutropenia in a sub…
DOI: 10.1016/j.msard.2020.101980 -
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
This randomized, multicenter trial in elderly patients with untreated diffuse large B-cell lymphoma shows that adding rituximab to CHOP improves complete response rates and prolongs event-free and overall survival without a clinically meaningful rise in toxicity, compared with C…
DOI: 10.1056/nejmoa011795 -
Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease
Rituximab plus liposomal doxorubicin (R-Dox) yields high clinical, biochemical, and radiographic responses with acceptable safety in HIV-infected patients with symptomatic KSHV-associated multicentric Castleman disease, including concurrent Kaposi sarcoma, in a 17-patient pilot …
DOI: 10.1182/blood-2014-07-586800 -
Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review
This is a comprehensive systematic review (including RCTs, open-label trials, observational studies and case reports) evaluating the safety profile of ocrelizumab in multiple sclerosis, detailing infection risks, infusion-related reactions, discontinuations due to adverse events…
DOI: 10.1080/14740338.2020.1807002 -
Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis
A randomized, double-blind, single-center trial comparing rituximab induction followed by glatiramer acetate monotherapy versus glatiramer acetate alone in relapsing multiple sclerosis with active disease, showing an early advantage in No Evidence of Disease Activity (NEDA) and …
DOI: 10.1212/wnl.0000000000006916 -
Incidence, Clinical Features, and Outcomes of Late‐Onset Neutropenia From Rituximab for Autoimmune Disease
In a large single-center retrospective cohort of 738 adults with autoimmune disease treated with rituximab-induced continuous B cell depletion, the study found a 6.6% one-year incidence of late-onset neutropenia (LON), identified systemic lupus erythematosus and concurrent cyclo…
DOI: 10.1002/art.41501 -
Rituximab associated late-onset neutropenia—a rheumatology case series and review of the literature
This study investigates the incidence and characteristics of late-onset neutropenia (LON) in patients with rheumatic diseases treated with rituximab, finding a 6.5% incidence rate and suggesting that LON is typically not associated with serious infections or adverse outcomes.
DOI: 10.1007/s10067-016-3313-y -
Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab
This study investigates the rate of hepatitis B virus (HBV) reactivation in HBsAg-negative/anti-HBc-positive lymphoma patients undergoing chemotherapy with or without rituximab, finding a significant incidence of reactivation associated with rituximab treatment.
DOI: 10.1200/JCO.2008.18.0182 -
Hepatitis B screening before rituximab therapy: a multicentre South Australian study of adherence
A multicentre retrospective study in South Australia evaluating adherence to hepatitis B screening before rituximab therapy, the prevalence of HBV infection among rituximab recipients, and outcomes of at-risk patients, revealing poor screening adherence but a low HBV reactivatio…
DOI: 10.1111/imj.13740 -
Hepatitis B reactivation in HBsAg‐negative/HBcAb‐positive patients receiving rituximab for lymphoma: a meta‐analysis
This meta-analysis estimates the risk of hepatitis B virus (HBV) reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma, finding a pooled reactivation rate of 6.3% and highlighting significant heterogeneity across studies.
DOI: 10.1111/jvh.12402 -
A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma
This systematic review and meta-analysis of 12 randomized controlled trials (4,996 patients) found that rituximab plus chemotherapy (R-chemo) improved overall survival, overall response, complete response, and disease control compared to chemotherapy alone in patients with B-cel…
DOI: 10.3109/02841860903150502 -
An Update on the Incidence, Risk Factors and Mechanisms of Rituximab- Associated Neutropenia
This article provides an updated synthesis of rituximab-associated neutropenia (RAN), detailing its incidence, risk factors, proposed mechanisms, clinical features, management, and gaps across autoimmune diseases, hematologic malignancies, and transplant settings, with emphasis …
DOI: 10.5114/aoms/152174